Trial Profile
Phase II Trial of Pembrolizumab (MK-3475) With GM-CSF Induction in Advanced Biliary Cancers
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Sargramostim (Primary)
- Indications Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 22 Jan 2022 Final Results presented at the 2022 Gastrointestinal Cancers Symposium
- 22 Jan 2022 Primary endpoint has not been met (Overall response rate (ORR), as per results presented at the 2022 Gastrointestinal Cancers Symposium
- 13 Dec 2021 Status changed from active, no longer recruiting to completed.